American Association for Cancer Research
crc-24-0047-s10.xlsx (172.17 kB)

Supplementary Table S6 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

Download (172.17 kB)
posted on 2024-06-05, 14:20 authored by Zhanfang Guo, Jingqin Luo, R. Jay Mashl, Jeremy Hoog, Piyush Maiti, Nikki Fettig, Sherri R. Davies, Rebecca Aft, Jason M. Held, Ramaswamy Govindan, Li Ding, Shunqiang Li, Cornelius von Morze, Gerburg M. Wulf, Kooresh I. Shoghi, Cynthia X. Ma

Statistical Analysis Comparing Changes in the Levels of Proteins by RPPA Among Different Treatment Groups for 8 PDX Models


HHS | NIH | NCI | Cancer Moonshot (Misión contra el Cáncer)

HHS | NIH | NCI | Center for Cancer Research (CCR)

Stichting A Sister's Hope (A Sister's Hope)



The PI3K pathway regulates essential cellular functions and promotes chemotherapy resistance. Activation of PI3K pathway signaling is commonly observed in triple-negative breast cancer (TNBC). However previous studies that combined PI3K pathway inhibitors with taxane regimens have yielded inconsistent results. We therefore set out to examine whether the combination of copanlisib, a clinical grade pan-PI3K inhibitor, and eribulin, an antimitotic chemotherapy approved for taxane-resistant metastatic breast cancer, improves the antitumor effect in TNBC. A panel of eight TNBC patient-derived xenograft (PDX) models was tested for tumor growth response to copanlisib and eribulin, alone or in combination. Treatment-induced signaling changes were examined by reverse phase protein array, immunohistochemistry (IHC) and 18F-fluorodeoxyglucose PET (18F-FDG PET). Compared with each drug alone, the combination of eribulin and copanlisib led to enhanced tumor growth inhibition, which was observed in both eribulin-sensitive and -resistant TNBC PDX models, regardless of PI3K pathway alterations or PTEN status. Copanlisib reduced PI3K signaling and enhanced eribulin-induced mitotic arrest. The combination enhanced induction of apoptosis compared with each drug alone. Interestingly, eribulin upregulated PI3K pathway signaling in PDX tumors, as demonstrated by increased tracer uptake by 18F-FDG PET scan and AKT phosphorylation by IHC. These changes were inhibited by the addition of copanlisib. These data support further clinical development for the combination of copanlisib and eribulin and led to a phase I/II trial of copanlisib and eribulin in patients with metastatic TNBC. In this research, we demonstrated that the pan-PI3K inhibitor copanlisib enhanced the cytotoxicity of eribulin in a panel of TNBC PDX models. The improved tumor growth inhibition was irrespective of PI3K pathway alteration and was corroborated by the enhanced mitotic arrest and apoptotic induction observed in PDX tumors after combination therapy compared with each drug alone. These data provide the preclinical rationale for the clinical testing in TNBC.